Safety and efficacy of the combination of erlotinib and sirolimus for the ... - UroToday Print
UroTodayThe mammalian target of rapamycin (mTOR) is an important therapeutic target in the treatment of renal cell carcinoma (RCC). Pre-clinical data indicate that

... read more